<DOC>
	<DOC>NCT01561937</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with warfarin to reach a targeted INR (International Normalization Ratio).</brief_summary>
	<brief_title>Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Warfarin</mesh_term>
	<criteria>INR below or equal to 1.2 The receipt of any investigational drug within 1 month prior to this trial Use of anticoagulation therapydefined as vitamin K antagonists, platelet antagonists, heparin (or low molecular weight heparin), aspirin or NSAIDs (NonSteroidal AntiInflammatory Drug) within 14 days prior to trial AfricanAmerican race Weight above 160 kg Supplemental Vitamin K use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>